AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 82 min read$MCK

TYLER BRIAN S. sold $6.7M of MCK

TYLER BRIAN S. (Chief Executive Officer) sold 8,463 shares of MCKESSON CORP (MCK) at $793.56 ($6.72M total) on 2026-07-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · TYLER BRIAN S.
Published Jul 8, 2026, 8:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 8, 2026, 8:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MCK
Neutral
medium confidence
Mentioned
$MCK
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MCKNeutralLow
01

Why it matters

Traders may monitor insider activity for sentiment, but 10b5-1 plans generally limit the informational content about near-term business performance.

02

Market read

A CEO open-market sale of about $6.72M in McKesson shares was reported, but it is scheduled under a 10b5-1 plan.

03

What to watch

The filing does not disclose reasons for the sale, and 10b5-1 schedules can be triggered regardless of current fundamentals or sentiment.

Relevance 5/10Novelty 5/10Timing: SEC Form 4 filed 2026-07-08 for a 2026-07-07 insider sale.

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for McKesson (MCK).

Company-level read

Ticker impact

$MCKNeutralMedium confidence
Context

McKesson CEO Tyler Brian S. filed a Form 4 selling 8,463 shares at $793.56 for about $6.72M under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this filing; any impact is likely short-lived.

Evidence & confidence

The transaction is an open-market sale by the CEO, explicitly under a pre-arranged Rule 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Sector

Minimal sector read-through; this is company-specific insider transaction data.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A large CEO sale can be interpreted as confidence in liquidity needs or diversification rather than negative outlook, especially with a 10b5-1 plan.

Key entities

  • issuer
    MCKESSON CORP

    Company whose CEO insider sale is disclosed on Form 4.

  • insider
    TYLER BRIAN S.

    McKesson CEO and director who sold shares.

  • trading mechanism
    Rule 10b5-1 plan

    Pre-arranged plan that typically reduces interpretive weight of insider sales.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MCK insider trading history →

Related articles

OCT 10
$OPCHHighAI 9/10

Option Care Health Sold for $5.8B in CD&R-McKesson Deal

Option Care Health (OPCH) is being acquired by CD&R and McKesson (MCK) for $5.8B, or $32.05 per share, a 37% premium. The deal, expected to close in 2027, values the company at $5.8B. Option Care Health will operate independently post-acquisition. The company reported $5.6B in 2025 revenue and $207.6M in net income, with modest growth in 2026. The acquisition aligns with McKesson's strategy to expand access to innovative therapies.

hoodline.com2 min
OCT 9
$MCKHighAI 9/10

McKesson (MCK) Joins $5.8 Billion Option Care Health (OPCH) Acquisition. Is the Valuation Justified?

McKesson (MCK) is acquiring Option Care Health (OPCH) for $5.8B, including debt, at $32.05 per share, a 37% premium. McKesson and private equity firm CD&R will own 49% and 51% respectively. The deal expands McKesson's specialty healthcare services. McKesson's Q1 2027 revenue was $105.4B, beating estimates, with adjusted EPS up 20% YoY to $9.93. The company raised its fiscal 2027 adjusted EPS guidance to $44.20-$45.00.

finance.yahoo.com2 min
OCT 8
$MCKHighAI 9/10

McKesson & CD&R Acquire Leading US Home-Infusion Platform

McKesson and private equity firm CD&R will acquire Option Care Health, a US home-infusion care provider, for $5.8bn. CD&R will take a majority stake, while McKesson invests $1.4bn for a minority stake. The deal values Option Care Health at $32.05 per share and is expected to close in H1 2027. McKesson aims to leverage the acquisition to expand its specialty care offerings.

healthcare-digital.com3 min
OCT 7
$OPCHHighAI 9/10

Option Care stock surges on McKesson's home-infusion bet

Option Care Health (OPCH) shares rose 33% to $31.11 after McKesson (MCK) and Clayton, Dubilier & Rice agreed to take it private for $32.05 per share, valuing it at $5.8B. McKesson will initially own 49%, with an option to acquire the rest later. The deal gives McKesson access to Option Care's home-infusion network, serving 315K+ patients. Option Care's Q2 revenue grew 1.9% to $1.44B. The deal needs shareholder and regulatory approvals to close in early 2027.

finance.yahoo.com2 min
OCT 7
$MCKHighAI 9/10

McKesson Plans $1.4 Billion Stake in $5.8 Billion Option Care Buyout

McKesson plans a $1.4B investment for a 49% stake in Option Care Health, part of a $5.8B buyout by Clayton, Dubilier & Rice. Shareholders will receive $32.05 per share. The deal, pending approvals, is expected to close in early 2027. Option Care shares rose 32.7% on the news. McKesson's Q1 revenue grew 8% to $105.4B, with net income down 22% to $614M.

finchannel.com2 min